Jean H. Tayar, MD, RhMSUS, FACP, FACR
Department of General Internal Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Professor with Multi-Year Appointment Award, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Adjunct Professor, Department of Medicine, Baylor College of Medicine, Houston, TX
Dual/Joint/Adjunct Appointment
Professor with Multi-Year Appointment Award, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Adjunct Professor, Department of Medicine, Baylor College of Medicine, Houston, TX
Education & Training
Degree-Granting Education
| 1997 | Saint Joseph University-Faculty of Medicine, Beirut, LB, MD |
Postgraduate Training
| 2022-2023 | LEADing Teams Core Curriculum, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2014-2015 | Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2009-2009 | Clinical Safety and Effectiveness Program, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2009-2009 | Junior Heart of Leadership Program, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2008-2010 | Clinical Research Curriculum, The University of Texas Medical School, Houston, Texas |
| 2002-2004 | Clinical Fellowship, Rheumatology, State University of New York Health Science Center at Brooklyn, Brooklyn, New York |
| 2001-2002 | Chief Medical Resident, Internal Medicine, Staten Island University Hospital, Staten Island, New York |
| 1999-2001 | Clinical Residency, Internal Medicine, Staten Island University Hospital, Staten Island, New York |
| 1998-1999 | Clinical Internship, Internal Medicine, Staten Island University Hospital, Staten Island, New York |
| 1997-1998 | Residency, Internal Medicine, Hotel Dieu de France Hospital, Beirut |
Licenses & Certifications
| 2023 | Georgia Medical License |
| 2023 | Oklahoma Medical License |
| 2023 | Arizona Medical License |
| 2023 | Tennessee Medical License |
| 2023 | Alabama Medical License |
| 2023 | Washington Medical License |
| 2023 | Mississippi Medical License |
| 2021 | Florida Medical License |
| 2015 | Maintenance of Certification, American Board of Internal Medicine, Rheumatology |
| 2015 | Musculoskeletal Ultrasound Certification in Rheumatology, American College of Rheumatology |
| 2011 | Maintenance of Certification, American Board of Internal Medicine, Internal Medicine |
| 2008 | Texas Medical License |
| 2005 | American Board of Internal Medicine Rheumatology Board |
| 2004 | Louisiana Medical License |
| 2001 | American Board of Internal Medicine, Internal Medicine |
| 1996 | Educational Commission Foreign Medical Graduates Certificate |
Experience & Service
Faculty Academic Appointments
Associate Professor with Multi- Year Appointment Award, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2020
Assistant Professor, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2014
Administrative Appointments/Responsibilities
Section Chief, Section of Rheumatology and Clinical Immunology, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Deputy Quality Officer, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2020
Patient Experience Officer, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2020
Education Director (Department level), General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2022
Clinical Medical Director, Internal Medicine Center - Mays Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - Present
Director, MD Anderson Rotation Site, Baylor College of Medicine Rheumatology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - Present
Director, Observership Program, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2022
Director, Moonlighting Program, General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2013
Other Professional Positions
NCI Head and Neck Cancer Steering Committee (HNSC), National Cancer Institute, Rockville, MD, 2022 - Present
Consultant, Oxford Immunotec, Marlborough, MA, 2016 - 2017
Member, Certification Appeals Committee, American College of Rheumatology, Musculoskeletal Ultrasound Certification Program, Atlanta, GA, 2012 - 2018
Private Practice, Rheumatology and Internal Medicine, Oakdale Community Hospital, Oakdale, LA, 2005 - 2008
Extramural Institutional Committee Activities
Member, Clinical Faculty Review Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2025
Member, SARS-CoV-2 Associated Multisystem Inflammatory Syndrome Working Management Algorithm Task Force, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, The Division of Internal Medicine Toxicity Working Group, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, IOTOX Clinical Management Working Group, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Internal Medicine Center Patient Advisory and Quality Improvement Council, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, General Internal Medicine Advisory Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present
Member, Division of Internal Medicine Clinical Administrative Advisory Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present
Member, Sedation and Procedures Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2017
Co-Chair, Internal Medicine Center Steering Committee, The University of Texas MD Anderson Cancer Center, 2012 - Present
Non-voting member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2010 - Present
Member, GME Institutional Review Subcommittee, The University of Texas MD Anderson Cancer Center, 2010 - Present
Member, Infection Control Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2020
Member, Infection Control Core Group, The University of Texas MD Anderson Cancer Center, 2008 - 2016
Honors & Awards
| 2024 | Weatherhead Executive Education: MD Anderson Cancer Center Leadership Institute Emotional Intelligence Certificate, Case Western Reserve University |
| 2021 | Top 1% Provider, Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) |
| 2021 | DOIM Excellence in Education Award, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center |
| 2021 | President’s Recognition of Faculty Excellence Award, Education & Mentorship Advancement, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center |
| 2018 | Multi-Year Appointment Award, The University of Texas MD Anderson Cancer Center |
| 2013 | Fellow of the American College of Physicians |
| 2013 | Educator of the Year, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center |
| 2004 | The Pfizer Scholars in Pain Management Award, NY |
| 2002 | Certificate of Merit, American Society of Internal Medicine, NY |
| 2002 | Distinguished Achievement in Medical Research and Scholarly Activity, Staten Island University Hospital, NY |
| 2001 | Case Report Award, Academy of Medicine of Richmond, NY |
| 2001 | Certificate of Merit, American Society of Internal Medicine, NY |
| 2001 | Case Report Award, Staten Island University Hospital |
| Certified Physician Executive (CPE) Certification, The University of Texas MD Anderson Cancer Center Leadership Institute | |
| Top 10% in the nation, Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2018. Rheumatology Update for the Primary Care Provider. Conference. Department of Family and Community Medicine. Houston, TX, US.
- 2017. Lesinurad in Combination with Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Standard of Care (the Multinational CLEAR 2 Study). Conference. Lesinurad in Combination with Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Standard of Care (the Multinational CLEAR 2 Study). Houston, TX, US.
- 2016. Ankylosing Spondylitis and Axial Spondyloarthritis. Conference. Ankylosing Spondylitis and Axial Spondyloarthritis. Houston, TX, US.
- 2015. Introduction to Musculoskeletal Ultrasound and its Role in Ultrasound Guided Injection. Conference. Introduction to Musculoskeletal Ultrasound and its Role in Ultrasound Guided Injection. Houston, TX, US.
- 2015. Introduction to Musculoskeletal Ultrasound and its Role in Ultrasound Guided Injection. Conference. Introduction to Musculoskeletal Ultrasound and its Role in Ultrasound Guided Injection. Houston, TX, US.
- 2014. Arthroscopic Partial Meniscectomy Versus Sham Surgery for a Degenerative Meniscal Tear. Conference. Arthroscopic Partial Meniscectomy Versus Sham Surgery for a Degenerative Meniscal Tear. Houston, TX, US.
- 2013. Systemic Lupus Erythematosus. Conference. Systemic Lupus Erythematosus. Houston, TX, US.
- 2013. ACR Guidelines for Management of Gout. Conference. ACR Guidelines for Management of Gout. Houston, TX, US.
- 2013. IgG4 Related Diseases. Conference. IgG4 Related Diseases. Houston, TX, US.
- 2013. Paraneoplastic Syndromes. Conference. Paraneoplastic Syndromes. Houston, TX, US.
- 2012. Billing Compliance Education Tutorial Session. Conference. Billing Compliance Education Tutorial Session. Houston, TX, US.
- 2012. Recommendations for the Management of Mixed Cryoglobulinemia Syndrome in Hepatitis C Virus-infected Patients. Conference. Recommendations for the Management of Mixed Cryoglobulinemia Syndrome in Hepatitis C Virus-infected Patients. Houston, TX, US.
- 2012. The Appropriate Use of Non-Steroidal Anti-Inflammatory Drugs in Rheumatic Disease: Opinions of a Multidisciplinary European Expert Panel. Conference. The Appropriate Use of Non-Steroidal Anti-Inflammatory Drugs in Rheumatic Disease: Opinions of a Multidisciplinary European Expert Panel. Houston, TX, US.
- 2011. Introduction to Musculoskeletal Ultrasound. Conference. Introduction to Musculoskeletal Ultrasound. Houston, TX, US.
- 2011. Emergency Center Observation Unit. Conference. Emergency Center Observation Unit. Houston, TX, US.
- 2011. A Randomized, Double-Blind, Parallel-Group, Multicenter Study. Conference. A Randomized, Double-Blind, Parallel-Group, Multicenter Study. Houston, TX, US.
- 2010. New RA Classification Criteria. Conference. New RA Classification Criteria. Houston, TX, US.
- 2009. Emergency Center Observation Unit. Conference. Emergency Center Observation Unit. Houston, TX, US.
- 2009. Febuxostat in the Treatment of Gout. Conference. Febuxostat in the Treatment of Gout. Houston, TX, US.
National Presentations
- 2025. Miscellaneous Rheumatic & Inflammatory Diseases Poster I - Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T Cells Contribute to Recurrent Immune Checkpoint Inhibitor Mediated Inflammatory Arthritis. Poster. American College of Rheumatology Annual Meeting. Chicago, Illinois, US.
- 2025. Infection-related Rheumatic Disease Poster - A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint Injections in Cancer Patients. Poster. ACR Convergence. Chicago, Illinois, US.
- 2025. Immune-Related Adverse Events: Evolving Strategies Amid Controversy. Invited. 21st Annual Medical & Scientific Meeting. Long Beach, CA, US.
- 2023. Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis. Conference. Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis. San Diego, CA, US.
- 2022. Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma. Conference. Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma. Philadelphia, PA, US.
International Presentations
- 2018. Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Conference. Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Amsterdam, NL.
- 2017. IGG4-Related Disease, New Insight. Conference. Lebanese Order of Physicians. Beirut, LB.
- 2016. Tuberculosis Testing in Patients with Rheumatic Disease: A Case-Based, Interactive Session. Conference. Oxford Immunotec. London, GB.
Formal Peers
- 2019. Immune Related Adverse Events: An Overview. Visiting. Minneapolis, MN, US.
- 2019. Rheumatic Immune Adverse Events. Invited. Minneapolis, MN, US.
- 2019. Wrist and Hand Ultrasound & Hands On. Invited. Minneapolis, MN, US.
- 2018. Wrist and Hand Ultrasound & Hands On. Invited. Minneapolis, MN, US.
- 2016. Primary Biliary Cholangitis and Bone Health. Invited. Houston, TX, US.
- 2012. Musculoskeletal Ultrasound in Rheumatology. Visiting. Brooklyn, NY, US.
Selected Publications
Peer-Reviewed Articles
- Keam S, Li YJ, Chu Y, Tayar JH, Lu H, Wu M, Agarwal SK, Jain N, Msaouel P, Diab A, Wang L, Haymaker C, Nurieva R, Kim ST. Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis. Cancer Immunol Res, 2026. e-Pub 2026. PMID: 42536056.
- Koyfman SA, Bauman JE, Mohseni M, Amit M, Dadhania DM, Demehri S, Divi V, Geiger JL, Hanna GJ, Kushalani N, Lipson EJ, Mannon RB, Migden M, Schmalbach CE, Swiecicki PL, Tayar JH, Tsai KY, Wuthrick EJ, Malik S, Gross ND. Summary recommendations from the NCI clinical trials planning meeting (CTPM) on advanced cutaneous squamous cell carcinoma in immunosuppressed patients. JNCI, 2026. e-Pub 2026. PMID: 42478754.
- Li J, Buni M, Tayar J, Lu H, Davie M, Gay CM, Elamin Y, Huey R, Jonasch E, Assassi S. A case series of Raynaud’s phenomenon in the setting of Immune Checkpoint Inhibitors. e-Pub 2026.
- Li YJ, Lopez-Olivo MA, Geng Y, Tayar JH, Suarez-Almazor ME. Dose reduction and discontinuation of non-tumor necrosis factor (TNF) biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for people with rheumatoid arthritis in remission or low disease activity. Cochrane Database Syst Rev 5(5):CD014173, 2026. e-Pub 2026. PMID: 42159078.
- Lopez-Olivo, MA, Matusevich, AR, Tayar, JH, Lu, H. Managing Rheumatoid Arthritis in Older Adults with Cancer. Drugs and Aging 42(7):599-614, 2025. e-Pub 2025. PMID: 40382733.
- Li Y J, Prieto VG, Tayar J. Case of new-onset scleromyxoedema-scleroedema spectrum disorder in a patient with CLL. RMD Open. RMD Open 9(9):4, 2023. e-Pub 2023. PMID: 38016711.
- Lopez-Olivo, MA, Kachira, JJ, Buni, M, Kim, ST, Lu, H, Tayar, JH, Duhon, GF, Ruiz, JI, Bingham, CO, Calabrese, C, Volk, R, Suarez-Almazor, M. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers 15(15), 2023. e-Pub 2023. PMID: 37568819.
- Lopez-Oliva MA, Kachira JJ, Buni M, Kim ST, Lu H, Tayar JH, Duhon GF, Ruiz JI, Bingham III CO, Calabrese C, Volk RJ, Suarez-Almazor ME. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers, 2023. e-Pub 2023.
- Faak, F, Buni, M, Falohun, A, Lu, H, Song, J, Johnson, DH, Zobniw, C, Trinh, VA, Awiwi, M, Tahon, NH, Elsayes, KM, Ludford, K, Montazari, EJ, Chernis, J, Dimitrova, M, Sandigursky, S, Sparks, JA, Abu-Shawer, O, Rahma, OE, Thanarajasingam, U, Zeman, AM, Talukder, R, Singh, N, Chung, SH, Grivas, PD, Daher, M, Abudayyeh, A, Osman, I, Weber, JS, Tayar, JH, Suarez-Almazor, M, Hassan, NA, Diab, A. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. Journal for immunotherapy of cancer 11(6), 2023. e-Pub 2023. PMID: 37328287.
- Martel J, Cho WC, Runge JS, Patel AB, Tayar J, Woodman K, Hume CB, Curry J, Heberton M. Durvalumab-associated generalized morphea with overlapping vitiligo. JAAD Case Reports 30:83-86, 2022. e-Pub 2022.
- Robinson JD, Karam-Hage M, Kypriotakis G, Beneventi D, Blalock JA, Cui Y, Gonzalez R, Tayar J, Chaftari P, Cinciripini PM. Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center. Am J Addict 31(3):236-241, 2022. e-Pub 2022. PMID: 35347796.
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
- Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Glitza Oliva IC, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022. e-Pub 2022.
- DiPeri TP, Demirhan M, Karp DD, Fu S, Hong DS, Subbiah V, Lim J, Ballester LY, Tayar JH, Suarez-Almazor ME, Javle M, Meric-Bernstam F. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol 5(1):26-30, 2022. e-Pub 2022. PMID: 35663835.
- DiPeri TP, Demirhan M, Karp DD, Fu S, Hong DS, Subbiah V, Lim J, Ballester LY, Tayar JH, Suarez-Almazor ME, Javle M, Meric-Bernstam F. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. Journal of Immunotherapy and Precision Oncology 5(1):26-30, 2022. e-Pub 2022.
- Abdel-Wahab N, Diab A, Yu RK, Futreal A, Criswell LA, Tayar JH, Dadu R, Shannon V, Shete SS, Suarez-Almazor ME. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021. e-Pub 2021. PMID: 33409738.
- Kim ST, Tayar J, Fu S, Ke D, Norry E, Sun A, Miller J, Hong DS. Newly developed pseudogout arthritis after therapy with MAGE- A4 directed TCR T cells responded to treatment with tocilizumab. Journal for ImmunoTherapy for Cancer 9:e002716. doi:10.1136/jitc-2021-002716, 2021. e-Pub 2021.
- Pundole X, Zamora N, Siddhanamatha H, Lin H, Tayar J, Leung CH, Li L, Suarez-Almazor M. Overall Survival in Patients with Rheumatoid Arthritis and Solid Malignancies Receiving Biologic Disease-Modifying Antirheumatic Therapy. Clinical Rheumatology, 2020. e-Pub 2020.
- Abdel-Wahab N, Tayar JH, Fa'ak F, Sharma G, Lopez-Olivo MA, Yousif A, Shagroni T, Al-Hawamdeh S, Rojas-Hernandez CM, Suarez-Almazor ME. Systematic Review of Observational Studies Reporting Antiphospholipid Antibodies in Patients with Solid Tumors. Blood Adv 4(8):1746-1755, 2020. e-Pub 2020. PMID: 32337583.
- Pundole X, Zamora NV, Siddhanamatha H, Lin H, Tayar J, Hong LC, Li L, Suarez-Almazor ME. Utilization of Biologic Disease-Modifying Anti-rheumatic Drugs in Patients with Rheumatoid Arthritis and Cancer. Clin Rheumatol, 2020. e-Pub 2019. PMID: 31853733.
- Zamora NV, Tayar J, Lopez-Olivo MA, Christensen R, Suarez-Almazor M. Baricitinib for Rheumatoid Arthritis. Cochrane Database Syst Rev, 2019. e-Pub 2019.
- Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME. Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 48(4):736-740, 2019. e-Pub 2019. PMID: 29909921.
- Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7(1):2, 2019. e-Pub 2019. PMID: 30612580.
- Donisan T, Balanescu DV, Mouhayar E, Tayar J, Iliescu C. Coronary Lesions in Takayasu Arteritis with Chronic Myelogenous Leukemia - Intravascular Assessment With Optical Coherence Tomography and Fractional Flow Reserve. Circ J 83(1):245-246, 2018. e-Pub 2018. PMID: 29952342.
- Karam-Hage M, Kypriotakis G, Robinson JD, Green CE, Mann G, Rabius V, Wippold R, Blalock JA, Mouhayar E, Tayar J, Chaftari P, Cinciripini PM. Improvement of Smoking Abstinence Rates with Increased Varenicline Dosage: A Propensity Score-Matched Analysis. J Clin Psychopharmacol 38(1):34-41, 2018. e-Pub 2018. PMID: 29232312.
- Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, Johnson DH, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis 76(12):2061-2064, 2017. e-Pub 2017. PMID: 28830882.
- El Chaer F, Mori N, Shah D, Oliver N, Wang E, Jan A, Doan V, Tverdek F, Tayar J, Ariza-Heredia E, Chemaly RF. Adjuvant and Salvage Therapy with Leflunomide for Recalcitrant Cytomegalovirus Infections in Hematopoietic Cell Transplantation Recipients: A Case Series. Antiviral Res, 2016. e-Pub 2016. PMID: 27594527.
- Tang VK, Huh YO, Tayar J, Rojas Hernandez CM. Primary autoimmune myelofibrosis as etiology of pancytopenia mimicking myelodysplastic syndrome. Leuk Lymphoma 57(3):731-4, 2016. e-Pub 2016. PMID: 26422082.
- Mouhayar E, Tayar J, Fasulo M, Aoun R, Massey M, Abi-Aad S, Iliescu C, Ahrar K, Huynh T. Outcome of Acute Limb Ischemia in Cancer Patients. Vasc Med 19(2):112-117, 2014. e-Pub 2014. PMID: 24532704.
- Lopez-Olivo MA, Tayar J, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME. Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Biologic Therapy: A Meta-analysis. JAMA 9(308):898-908, 2012. e-Pub 2012. PMID: 22948700.
- Tayar J, Lopez-Olivo M, Suarez-Almazor ME. Febuxostat for the Treatment of Chronic Gout. Cochrane Database Syst Rev, 2012. e-Pub 2012.
- Sweeney SA, Kumar VA, Tayar J, Weber DM, Safdar A, Alonso C, Hymes S. Case 181: Synovitis Acne Pustulosis Hyperostosis Osteitis (SAPHO) Syndrome. Radiology 2(763):613-17, 2012. e-Pub 2012. PMID: 22517965.
Invited Articles
- Lopez-Olivo MA, Lu L, Tayar J. Review of Tofacitinib in Rheumatoid Arthritis. Clinical Investigation 5(1):23-38, 2015. e-Pub 2015.
- Tayar J, Lopez-Olivo MA, Suarez-Almazor ME. Adalimumab; Eight Years of Experience in Rheumatoid Arthritis. International Journal of Clinical Rheumatology 8(2):164-184, 2013. e-Pub 2013.
- Lopez-Olivo MA, Tayar J. Safety Concerns on the Use of Biologic Drugs for the Treatment of Rheumatoid Arthritis. CML Rheumatology 31(4):101-16, 2012. e-Pub 2012.
- Tayar J, Suarez-Almazor M. New Understanding and Approaches to Treatment in Rheumatoid Arthritis. British Medical Bulletin(94):201-14, 2010. e-Pub 2010.
- Tayar J, Suarez-Almazor M. Rheumatoid Arthritis in Women: Current Approach and Overview of Recent Guidelines. The Female Patient 9(34):16-20, 2009. e-Pub 2009.
Review Articles
- Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar J, Dailey Garnes N, Petropoulos D, Tewari P, Bhatti M, Ahmad AH, Cortes J, Razvi S, McBeth K, Swinford R, Shoberu B, Waseemuddin W, Chi L, Gill JB, Zaky W, Daw N, Gutierrez C, Tereffe W, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Mahadeo KM. Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Front Oncol 11:625707, 2021. e-Pub 2021. PMID: 33614514.
- Tayar JH, Suarez-Almazor ME. New understanding and approaches to treatment in rheumatoid arthritis. Br Med Bull 94:201-14, 2010. e-Pub 2010. PMID: 20200013.
Professional Educational Materials
- Ginzler E, Tayar J. Systemic Lupus Erythematosus (Lupus), 2004.
Other Articles
- Kim, ST, Chu, Y, Misoi, MW, Suarez-Almazor, M, Tayar, JH, Lu, H, Buni, M, Kramer, J, Rodriguez, E, Hussain, Z, Neelapu, SS, Wang, RJ, Shah, AY, Tannir, NM, Campbell, M, Gibbons, DL, Cascone, T, Lu, C, Blumenschein, GR, Altan, M, Lim, B, Valero, V, Loghin, ME, Tu, J, Westin, SN, Naing, A, Garcia-Manero, G, Hassan, NA, Tawbi, H, Hwu, P, Oliva, IC, Davies, MA, Patel, SP, Zou, J, Futreal, A, Diab, A, Wang, L, Nurieva, R Author Correction. Nature communications 15(1), 2024. PMID: 38965214.
- Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME Febuxostat for treating chronic gout. Cochrane Database Syst Rev 11(11):CD008653, 2012. PMID: 23152264.
Editorials
- Lopez-Olivo MA, Tayar JH, Suarez-Almazor ME. The Updated Guidelines on the Use of Rituximab in Rheumatoid Arthritis. Rheumatology (Oxford) 50(12):2153-4, 2011. PMID: 21546350.
Abstracts
- Li YJ, Buni M, Tayar J, Lu H, Assassi S. Raynaud’s phenomenon in the setting of immune checkpoint inhibitors: A case series and possible implications. 9th World Congress on Systemic Sclerosis 11(1):194, 2026. e-Pub 2026.
- Thimmapuram R, Buni M, Lu H, Tayar J, Li J, Suarez-Almazor M, Rico R, Turner N, Nurieva R. Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis. American College of Rheumatology, 2023.
- Khawaja F, Chaftari P, Batista M, Tayar J, Chemaly R. Outcomes of Respiratory Viral Infections in Cancer Patients on PD-1 inhibitors. 2019 ID Week, 2019. e-Pub 2019.
- Kim ST, Tayar J, Lu HL, Suarez-Almazor M, Rodriguez E, Manero SS, Tawbi HA, Hwu P, Diab A, Nurieva R. Expansion of IL-17 Producing CD4+ T Cells in Synovial Fluid From Patients With Arthritis Resulting From Combination Therapy of PD-1 and CTLA-4 Inhibitors. 2019 Keystone Symposia Conference, Breckenridge, CO, 2019. e-Pub 2019.
- Kim ST, Tayar J, Lu HL, Suarez-Almazor M, Y-Z Z, Rodriguez E, Neelapu S, Wang J, Shah AY, Tannir N, Gibbons DL, Manero SS, Tawbi HA, Hwu P, Futreal A, Diab A, Nurieva R, Zhongshan L. Enrichment of IL-17 Producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis after Anti-CTLA-4 and anti-PD-1 Combination Therapy. Arthritis Rheumatol, 2019. e-Pub 2019.
- Kim ST, Tayar J. Enrichment of IL-17 Producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis after Anti-CTLA-4 and Anti-PD-1 Combination (Poster). 2019 ACR/ARP Annual Meeting(Abstract Number: 697812), 2019. e-Pub 2019.
- Kim S, Tayar J, Lu H, Wang J, Gibbons D, Garcia-Manero G, Hwu P, Diab A, Nurieva R. Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Induced Arthritis. Arthritis Rheumatol 70(Suppl10), 2018. e-Pub 2018.
- Lopez-Olivo MA, Tayar J, Zamora NV, Suarez-Almazor M. Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Annals of the Rheumatic Diseases, 2018. e-Pub 2018.
- Pundole X, Tayar, J, Suarez-Almazor M. Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer. Arthritis Rheumatol, 2018. e-Pub 2018.
- Kim ST, Nurieva R, Tayar JH, Huifang HL, Wang J, Dibbons D, Garcia-Manero GG, Suarez Almazor M, Hwu P, Diab A. Characterization of Lymphoid Cells in Synovial Fluid from Cancer Patients with Immunotherapy-Associated Arthritis. J Immunother Cancer(Suppl), 2018. e-Pub 2018.
- Lopez-Olivo MA, Tayar J, Zamora, Pratt G, Suarez-Almazor M. Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Rheumatol 70(Suppl10), 2018. e-Pub 2018.
- Abdel-Wahab N, Tayar JH, Diab A, Kim ST, Lu H, Suarez-Almazor ME. The Outcome of Checkpoint Inhibitor Therapy in Patients with Cancer and Solid Organ Transplant: A Systematic Review of the Literature. J Clin Oncol 36(Suppl 5S), 2018. e-Pub 2018.
- Abdel-Wahab N, Tayar JH, Diab A, Kim ST, Lu H, Suarez-Almazor ME. Inflammatory Arthritis Induced by the use of Checkpoint Inhibitors for Immunotherapy of Cancer. J Immunother Cancer 2(Suppl5), 2017. e-Pub 2017.
- Zamora NV, Lopez-Olivo MA, Tayar J, Christensen R, Suarez-Almazor M. Comparative Effectiveness of Tofacitinib Versus Baricitinib in Rheumatoid Arthritis Using a Systematic Review and Network Meta-Analysis of Randomized Trials. Arthritis Rheumatol 69(Suppl10), 2017. e-Pub 2017.
- Shah M, Tayar J, Abdel-Wahab N, Suarez-Almazor M. Myositis as a Complication of Checkpoint Blockade at a Comprehensive Cancer Center. Arthritis Rheumatol 69(Suppl10), 2017. e-Pub 2017.
- Sang K, Diab, Uemura M, Garcia S, Hwu P, Tayar J. Successful treatment of arthritis induced by checkpoint inhibitors with ani-IL-6 receptor antibody: A case series. Annuals of Rheumatic Diseases 76(Suppl2), 2017. e-Pub 2017.
- Kypriotakis G, Karam-Hage M, Robinson JD, Green CE, Zheng D, Mann G, Rabius V, Wippold R, Blalock JA, Mouhayar E, Tayar J, Chaftari P, Cincirpini PM. Improvement of Smoking Abstinence Rates with Increased Varenicline Dosage: A Propensity Score Matched Analysis. Society and Research on Nicotine & Tobacco, 2017. e-Pub 2017.
- Garcia S, Diab A, Uemura M, Mcquail N, Trinh V, Tayar J. New onset polyarthritis secondary to pembrolizumab [anti-PD1 antibody] in a patient with metastatic melanoma successfully treated with IL-6 receptor [IL-6R] inhibitor. Rheumatology Winter Clinical Symposium, 2016. e-Pub 2016.
- Zamora NV, Tayar J, Lopez-Olivo MA, Christensen R, Suarez-Almazor M. Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Ann Rheum Dis 75(Suppl2):731, 2016. e-Pub 2016.
- Zamora NV, Siddhanamatha H, Barbo A, Tayar J, Lin H, Suarez-Almazor M. Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer. Arthritis Rheumatol 68(Suppl10), 2016. e-Pub 2016.
- Zamora NV, Tayar J, Lopez-Olivo MA, Christensen R, Suarez-Almazor M. Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Rheumatol 68(Suppl10), 2016. e-Pub 2016.
- Lopez-Olivo MA, Martinez-Lopez JA, Tayar J, Bavineni M, Fulton S, Suarez-Almazor ME. Adverse events with the use of radiotherapy in patients with connective tissue diseases and cancer: A systematic review and meta-analysis. Arthritis Rheumatol, Arthritis & Rheumatism, 2013. e-Pub 2013.
- Lopez-Olivo MA, Tayar J, Fulton S, Suarez-Almazor ME. Tofacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis & Rheumatism, 2013. e-Pub 2013.
- Lopez-Olivo MA, Martinez-Lopez JA, Tayar J, Bavineni M, Fulton S, Suarez-Almazor ME. A Meta-analysis on the Use of Radiotherapy in Patients with Connective Tissue Diseases and Cancer. Annuals of Rheumatic Diseases 73(3):565, 2013. e-Pub 2013.
- Maskatia R, Tayar J. Bone Turning Into Stone: A Case of Hepatitis C-Associated Osteosclerosis. Baylor College of Medicine Department of Medicine Research Symposium, 2012. e-Pub 2012.
- Chaftari P, Tayar J, Gupta A, Ivey R, Segal C, Willis CR. Emergency Center Observation Unit, Division of Internal Medicine Research Retreat, University of Texas MD Anderson Cancer Center, 2011. e-Pub 2011.
- Waimann CA, Olejeme KA, Tayar J, Lei X, Suarez-Almazor ME. Cancer Associated Myositis: Temporal Relationship, Survival and Risk of Cancer Recurrence. Kelsey Research Foundation 12th Annual Health Services & Outcomes Research Conference, 2011. e-Pub 2011.
- Waimann CA, Olejeme KA, Tayar J, Lei X, Suarez-Almazor ME. Cancer Associated Myositis: Temporal Relationship, Survival and Risk of Cancer Recurrence. Arthritis & Rheumatism 10(63):S88, 2011. e-Pub 2011.
- Lopez-Olivio M, Martinez-Lopez JA, Tayar J, et al. Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Biologic Therapy: Meta-Analysis of Controlled Trials. Arthritis & Rheumatism 10(63):S17, 2010. e-Pub 2010.
- Lopez-Olivo M, J T, Suarez-Almazor M. Febuxostat for the Treatment of Chronic Recurrent Gout.: Supplement to the "Annals of Rheumatic Diseases". EULAR Journal, 2010. e-Pub 2010.
- Chaftari P, Tayar J, Gupta A, Ivey R, Segal C, Willis CR. Emergency Center Observation Unit. Building the Bridge at the Quality Chasm, The University of Texas Conference on Quality Initiatives, 2009. e-Pub 2009.
- Tayar J. Pasteurella Multocida as a cause of recurrent batermia, 2002. e-Pub 2002.
- Tayar J. The Incidence of Major Adverse Events Occuring During the Wait Period for Sleep Studies, 2001. e-Pub 2001.
- Lopez-Olivo MA, Duan Z, Tayar JH, Volk RJ, Ostrin EJ, Xu Y, Giordano SH, Zhao H. Lung Cancer Screening in Rheumatoid Arthritis in Community Settings. European Alliance of Associations for Rheumatology (EULAR).
Book Chapters
- Lu, H, Linda Bobby, NP, Tayar, JH, Bowman, S, Kim, ST, Msaouel, P. Polymyalgia Rheumatica-Like Syndrome Post Immune Checkpoint Inhibitor Therapy, 433-438, 2025.
- Abudayyeh, A, Tayar, JH, Tchakarov, A. Acute Tubulointerstitial Nephritis Post Immune Checkpoint Inhibitor Therapy, 287-292, 2025.
Letters to the Editor
- Tayar J, Jabbour G, Saggi SJ. Severe Hyperosmolar Metabolic Acidosis Due to a Large Dose of Intravenous Lorazepam. N Engl J Med 16: 1253-1254, 2002.
- ME, Barnes BJ, Tayar J, Saggi SJ. Hyperosmolar Metabolic Acidosis and Intravenous Lorazepam. NEJM 11: 857-858, 2002.
Patient Reviews
CV information above last modified August 26, 2026